date:Mar 11, 2013
Evolva Holding SA announced that it has entered into an agreement with Cargill to jointly develop and commercialize fermentation-derived steviol glycosides. Cargill will be responsible for commercialization and has agreed to make a CHF 5 million (approximately USD 5.3 million) equity investment in Evolva.
Additionally, Evolva stands to receive up to USD 7.5 million in milestone payments and has the right to a 45% participation in the final business. If Evolva decides not to exercise this option